# BioAge Labs, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BioAge Labs, Inc.). ## Overview BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program, BGE-102, is aimed at obesity and other metabolic conditions, with a stated goal of creating treatments that complement GLP-1 agonists and address unmet needs such as oral combination therapy. The company also uses longitudinal human aging datasets and a discovery platform to identify and validate novel therapeutic targets. BioAge has no approved products and does not yet generate product sales, so its business model currently depends on research collaboration revenue, external funding, and future clinical success. ## Products & services • BGE-102 metabolic disease product candidate • Human aging-based target discovery platform • Novartis target discovery collaboration • Lilly platform target discovery collaboration • Preclinical and clinical-stage drug development - **Lead product candidate** (0%) — BGE-102 and related development work aimed at metabolic disease indications, including obesity. - **Discovery platform and target validation** (0%) — Human aging data analytics used to identify and validate novel therapeutic targets. - **Collaborative research agreements** (100%) — Partnerships such as the Novartis and Lilly collaborations that fund discovery work and may generate milestones and royalties. - **Preclinical and clinical development services** (0%) — Internal and outsourced R&D activities supporting candidate advancement through early-stage testing. - BGE-102, the company's lead product candidate - Discovery platform built on longitudinal human aging datasets - Target identification and validation collaborations - Preclinical and clinical development of metabolic disease therapies - Research funding and milestone-based collaboration arrangements ## Customers BioAge does not currently sell approved medicines to end customers; instead, its near-term counterparties are pharmaceutical partners that fund or co-develop target discovery work. Novartis is a key collaboration partner under an agreement that provides upfront payments, research funding, and potential milestones tied to target discovery and validation. Lilly is another strategic partner in molecule discovery, reflecting a business model centered on partnering rather than direct commercialization. If BGE-102 or future candidates are approved, the company would then need to sell through physicians, hospitals, payors, and patients, either directly or via a commercialization partner. - **Pharmaceutical collaboration partners** (primary) — Large pharma companies that pay for target discovery, validation, and optional licensing rights because BioAge's aging datasets can surface differentiated metabolic disease targets. - **Future commercialization partners** (secondary) — Potential licensees or co-marketing partners that would help fund late-stage development and market approved products if BioAge does not build its own sales force. - **Healthcare providers and payors** (emerging) — Physicians, hospitals, and reimbursement decision-makers that would influence adoption of any approved obesity or metabolic disease therapy. - **Patients with metabolic disease** (emerging) — End users for any approved therapy, especially obesity and related metabolic disease patients seeking differentiated treatment options. - Pharmaceutical partners that license or co-develop novel targets - Novartis as a collaboration counterparty for discovery and validation work - Lilly as a partner in molecule discovery for metabolic disease - Future physicians, hospitals, payors, and patients if a product is approved - Potential commercial partners that would market approved products ## Geography BioAge is headquartered in the United States and operates as a U.S.-based clinical-stage biotech company. Its main physical footprint includes office and lab space in Emeryville, California, which supports research and development activities. The company relies on third-party manufacturers located in China and India for preclinical and clinical supply, creating operational exposure to cross-border supply chains and geopolitical disruption. Because BioAge has no product sales today, geography matters mainly through where R&D is performed, where vendors are located, and where future regulatory and commercialization activities may occur. - United States headquarters and primary operating base - Emeryville, California office and lab lease through 2031 - Third-party manufacturing in China and India - Global collaboration and licensing model rather than local sales footprint - Future commercialization geography depends on product approvals and partners ## Strategy BioAge's strategy is to use human aging biology and longitudinal datasets to discover targets that can produce differentiated metabolic disease therapies. The company is prioritizing BGE-102 while also advancing additional platform targets and expanding the pipeline through internal discovery and partnerships. Collaboration with Novartis is central to monetizing the platform today, while Lilly and potential future partners broaden the target discovery engine and reduce single-asset dependence. Longer term, the company aims to move from discovery into clinical validation, regulatory approval, and, if successful, commercialization through either its own infrastructure or third-party partners. - **Advance BGE-102** (short-term) — The lead candidate is the most direct path to clinical value creation and future product revenue. - **Expand target discovery partnerships** (short-term) — Collaborations such as Novartis and Lilly provide funding, validation, and optional downstream economics while reducing sole reliance on one program. - **Broaden the pipeline from the aging platform** (medium-term) — A wider pipeline improves the odds of finding commercially viable metabolic disease assets and diversifies scientific risk. - **Prepare commercialization optionality** (medium-term) — If a candidate is approved, the company needs either a partner or its own sales and marketing capabilities to capture value. - Advance BGE-102 through development as the lead asset - Use human aging biology to identify novel metabolic disease targets - Expand the pipeline through internal discovery and partnerships - Monetize the platform through collaboration revenue, milestones, and royalties - Build optionality for future commercialization or partnering - Maintain and defend intellectual property around discovered targets ## Risks BioAge faces the classic risks of a clinical-stage biotech: no approved products, no product revenue, and heavy dependence on successful clinical and regulatory outcomes. The company also relies on third-party CROs and CDMOs, including manufacturers in China and India, so supply disruptions, tariffs, geopolitical tensions, or quality failures could delay development or raise costs. Because it has never commercialized a product, it may struggle to build or outsource sales, reimbursement, and distribution capabilities if a candidate is approved. More broadly, the company is exposed to scientific risk, patent and IP disputes, trial execution risk, and the possibility that collaboration economics do not translate into durable value. - **Clinical development failure** [high] — BGE-102 and future candidates may not demonstrate sufficient safety or efficacy to advance, which would eliminate the main path to product revenue. - **Third-party manufacturing and supply chain disruption** [high] — The company relies on external manufacturers in China and India, so production issues, tariffs, or geopolitical events could delay trials or commercialization. - **Commercialization capability gap** [medium] — BioAge has no sales or marketing infrastructure and no prior commercialization experience, making post-approval execution uncertain. - **Intellectual property disputes** [medium] — Patent challenges or third-party infringement claims could require costly litigation or licensing and reduce economics from approved products. - **Funding and dilution risk** [high] — The company remains loss-making and depends on capital markets and collaboration funding to sustain R&D. - No approved products, so value depends on future clinical and regulatory success - Dependence on third-party CROs and CDMOs for trials and manufacturing - Supply chain exposure to China and India, including tariffs and geopolitical disruption - Commercialization risk because the company lacks sales and marketing infrastructure - Intellectual property disputes could force licensing costs or litigation - Clinical-stage biotech risk that programs fail to show efficacy or safety ## Accounting BioAge's most important accounting issue is revenue recognition for collaboration agreements, especially the Novartis arrangement, where upfront payments, research funding, and milestones must be allocated and recognized as performance obligations are satisfied. Because collaboration revenue can shift with the timing of work performed, quarterly results may be volatile and not comparable to a product company with recurring sales. R&D expense is the largest cost line and includes CRO, CDMO, consultant, and manufacturing spend, so reported operating losses are highly sensitive to trial timing and outsourced development activity. The company also has meaningful judgment in estimating deferred revenue, lease obligations for its Emeryville facility, and fair value changes on warrants or other financing-related instruments. - **Collaboration revenue under ASC 606** — Novartis deferred revenue and quarterly collaboration revenue - **Deferred revenue** — Balance sheet liabilities and future revenue timing - **R&D cost accruals and outsourced development spend** — Operating expenses and net loss - **Lease accounting** — Balance sheet lease liability and G&A expense - **Fair value measurement of warrants and financing instruments** — Other income (expense), net - Collaboration revenue recognition depends on performance obligations under Novartis - Deferred revenue reflects upfront and funded amounts not yet recognized - R&D expense is driven by outsourced clinical, preclinical, and manufacturing spend - Quarterly results can swing with timing of collaboration work and trial activity - Lease accounting matters for the Emeryville office and lab lease - Fair value changes on warrants and debt-related items can affect other income/expense --- *Last updated: 2026-08-11T04:46:23.736497+00:00*